Brind.

Cantor Fitzgerald initiated coverage with a Buy rating on BridgeBio regarding its drug treatment for genetic diseases.

2 reports, 2 independent Updated Aug 29

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Cantor Fitzgerald initiated coverage with a Buy rating on BridgeBio regarding its drug treatment for genetic diseases.

Who's involved

What this event is mainly about

BridgeBio Cantor Fitzgerald

Keep exploring

The entities involved

BridgeBio
company in Palo Alto, United States
- BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
Cantor Fitzgerald
American financial services company
- SoundHound is listed on the Nasdaq stock exchange, and its CEO has outlined the company's acquisition strategy.Mon 04:01
- Analyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Sun 18:41

Coverage

Newest first; wire copies grouped

Aug 29Insider MonkeyHere’s What Wall Street Thinks About BridgeBio Pharma (BBIO) BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 5, BridgeBio Phar
Aug 17Simply Wall St.BridgeBio Pharma, Inc. (NASDAQ:BBIO) Is Expected To Breakeven In The Near Future Explore BridgeBio Pharma's Fair Values from the Community and select yours BridgeBio Pharma, Inc. (NASDAQ:BBIO) is pos